CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,596,276 | +4.2% | 189,387 | +28.9% | 0.05% | +10.9% |
| Q2 2023 | $8,247,471 | +15.8% | 146,909 | -6.7% | 0.05% | -4.2% |
| Q1 2023 | $7,121,283 | +6.4% | 157,446 | -4.4% | 0.05% | -14.3% |
| Q4 2022 | $6,693,104 | -1.0% | 164,652 | +59.2% | 0.06% | -22.2% |
| Q3 2022 | $6,760,000 | +85.8% | 103,446 | +72.8% | 0.07% | +118.2% |
| Q2 2022 | $3,639,000 | +124.2% | 59,877 | +131.5% | 0.03% | +230.0% |
| Q1 2022 | $1,623,000 | -26.8% | 25,862 | -11.6% | 0.01% | -16.7% |
| Q4 2021 | $2,218,000 | -30.6% | 29,264 | +2.5% | 0.01% | -45.5% |
| Q3 2021 | $3,194,000 | -37.4% | 28,537 | -9.5% | 0.02% | -31.2% |
| Q2 2021 | $5,106,000 | – | 31,538 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |